Parkinsons Disease Essay -- Health

Parkinsons infirmity (PD) is a striatal dopamine deficiency disorder as a emergence of neuronal loss in the substania nigra. It is named after James Parkinson, a British apothecary, who first fully documented its physical signs in 1817. Since then, significant advances have been make in our understanding of characteristic pathophysiology as well as in the medical treatment of different stages of PD. An overview of condition features in terms of epidemiology, manifestations, diagnosis and disease management will be discussed in this paper.I.EpidemiologyParkinsons disease is a common form of Parkinsonism, affecting as many as one step up of every hundred people aged 65 years and over. The disease prevalence increases with age, with approximately 2% of those older than 80 years having PD. It is estimated that the number of patients diagnosed with PD is around 110,000 in the UK. No significant gender predominance has been recognised in most(prenominal) epidemiological studies althou gh some evidence implies that men are to a greater extent likely to develop PD than their counterparts. Owning to population aging, the incidence of PD is anticipated to rise dramatically in the coming decades. Despite being the second most common neurodegenerative illness after Alzheimers disease, the cause of PD remains elusive. To date, a considerable amount of literature has suggested that the disorder may be precipitated by either or both genetic and environmental factors (e.g. ingestion or inhalation of a neurotoxin called MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).II.ManifestationsParkinsons disease is classically characterised by the tetrad of clinical features, as follows bradykinesia or slowness of movement, rest tremor (usually described as pil... ...W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, steadfast effect in Adjunct therapy with Rasagiline Given Once daily, study) a randomised, double-blind, parallel-group trial. The Lancet. 12365(9463)94754. 10. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinsons disease a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000 Dec23(6)32430. 11. Oldfield V, Keating GM, Perry CM. Rasagiline a review of its use in the management of Parkinsons disease. Drugs. 200767(12)172547. 12. Chen JJ, Ly A-V. Rasagiline A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinsons disease. Am J wellness Syst Pharm. 2006 May 1563(10)91528.